Activity Overview
Generalized myasthenia gravis (gMG) is the most common acquired disorder of neuromuscular transmission, yet diagnosis is often delayed, and many patients are frequently misdiagnosed. Meanwhile, the therapeutic landscape has expanded beyond symptomatic therapies and broad immunosuppression. This archived recording of a live, accredited symposium was featured at the 2026 Carolina Neuromuscular Disease Summit, where expert faculty review the optimal diagnostic approach to suspected cases of gMG, including atypical and seronegative presentations. The discussion then examines guideline-directed management across available therapy classes and the patient-, disease-, and treatment-related factors that inform individualized selection, sequencing, and monitoring.
Target Audience
This activity is intended for neuromuscular specialists, neurologists, nurse practitioners, physician assistants, and nurses who treat neuromuscular diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement diagnostic strategies to identify patients with gMG
- Identify the role of newer agents in the management of patients with gMG
- Formulate individualized management plans for patients with generalized myasthenia gravis
Ali A. Habib, MD
Clinical Professor of Neurology
Director, Neuromuscular Medicine Fellowship
Program Director, Advanced Neuromuscular Medicine Fellowship
Neuromuscular Division
Department of Neurology
University of California
Irvine, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Alexion Pharmaceuticals/AstraZeneca, Amgen, Arcellx, argenx, Bristol Myers Squibb, Cabaletta Bio, Cartesian, Cour Pharmaceuticals, Grifols, Immunovant, Janssen/Johnson & Johnson, Merck, Nkarta, NMD Pharma, Novartis, Regeneron, UCB; Speakers Bureau: Alexion Pharmaceuticals, argenx, Janssen/Johnson & Johnson, UCB; Grant/Research Funding: Alexion Pharmaceuticals/AstraZeneca, Amgen, Arcellx, argenx, Bristol Myers Squibb, Cabaletta Bio, Cartesian, Cour Pharmaceuticals, Grifols, Immunovant, Janssen/Johnson & Johnson, Merck, Nkarta, NMD Pharma, Novartis, Regeneron, UCB; Ownership Interests in Publicly Traded Companies: Cartesian, Kyverna Therapeutics.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.